Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
- 1 December 2015
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 16 (16) , 1700-1710
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2014
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 studyThe Lancet Oncology, 2013
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabBreast Cancer Research and Treatment, 2012
- Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors.Journal of Clinical Oncology, 2011
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2008
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survivalJournal of Neuro-Oncology, 2008
- Survival in patients with brain metastases from breast cancerCancer, 2008
- Central Nervous System Metastases in HER-2–Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk FactorsThe Oncologist, 2007